Saturday 17 October 2026
Export IRMD’s income statement to Excel — free account
iRadimed Corporation
IRMD Healthcare Medical Devices
iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
88.27
1.10
−1.23%
Follow IRMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
52.51 | 51.75 | 54.96 | 42.61 |
+8 more quarters Free account |
P/S ratio |
14.15 | 14.26 | 14.77 | 11.24 | |
P/FCF ratio |
51.82 | 53.50 | 79.57 | 69.75 | |
P/Operating CF |
205.66 | 148.43 | 208.96 | 129.59 | |
P/B ratio |
12.01 | 12.49 | 13.08 | 9.20 | |
Price to Tangible BV |
12.43 | 12.92 | 13.57 | 9.53 | |
EV/Sales |
13.47 | 13.61 | 14.16 | 10.54 | |
EV/EBITDA |
39.84 | 39.96 | 43.44 | 32.85 | |
EV/Operating CF |
42.84 | 40.56 | 47.56 | 33.93 | |
EV/FCF |
49.31 | 51.05 | 76.28 | 65.40 | |
Quick Ratio |
7.89 | 5.76 | 6.37 | 5.50 | |
Current Ratio |
9.46 | 7.13 | 7.98 | 6.64 | |
Net Debt/EBITDA |
(8.69) | (7.33) | (6.84) | (7.83) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.78 | 0.80 | 0.81 | 0.77 | |
Operating CF/Net income |
1.14 | 1.42 | 0.92 | 1.25 | |
Capex/Depreciation |
(1.08) | (1.03) | (1.09) | (3.30) | |
Research and Development Expense of Revenue |
3.21% | 4.35% | 3.52% | 3.18% | |
Selling, General and Administrative Expense of Revenue |
39.64% | 39.22% | 40.27% | 42.38% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
3.94% | 3.11% | 3.07% | 3.14% | |
Graham Net Nets |
0.06 | 0.06 | 0.05 | 0.08 | |
Graham Number |
18.05 | 17.96 | 17.21 | 17.04 | |
Earnings Yield |
1.90% | 1.93% | 1.82% | 2.35% | |
Free Cash Flow Yield |
1.93% | 1.87% | 1.26% | 1.43% | |
Revenue per Share |
1.60 | 1.72 | 1.78 | 1.67 | |
Operating CF per Share |
0.46 | 0.65 | 0.47 | 0.55 | |
Capex per Share |
(0.03) | (0.04) | (0.03) | (0.10) | |
Free Cash Flow per Share |
0.43 | 0.61 | 0.43 | 0.45 | |
Cash per Share |
4.62 | 4.41 | 4.02 | 4.44 | |
Shareholders Equity per Share |
7.96 | 7.71 | 7.44 | 7.73 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.96 | 7.71 | 7.44 | 7.73 | |
Free Cash Flow |
5.50 | 7.82 | 5.51 | 5.72 | |
Working Capital |
77.56 | 74.30 | 71.02 | 72.12 | |
Capital Expenditures |
(0.44) | (0.47) | (0.42) | (1.26) | |
Net Current Asset Value |
73.50 | 70.55 | 67.05 | 68.55 | |
EV/EBIT |
42.19 | 42.00 | 45.38 | 34.15 | |
Capex to Sales |
0.02 | 0.02 | 0.02 | 0.06 | |
Price to Operating Income |
44.33 | 44.02 | 47.33 | 36.42 | |
| Other line items | |||||
Average Receivables |
12.06 | 13.06 | 12.11 | 12.11 | |
Average Payables |
1.88 | 2.39 | 1.86 | 1.87 | |
Average Inventory |
11.73 | 11.22 | 11.01 | 11.49 | |
Average Assets |
110.71 | 108.06 | 103.55 | 104.48 | |
Average Common Equity |
98.02 | 94.28 | 90.72 | 90.89 |
Columns are period end dates